Thermal therapy with immunotherapy for HER2-negative breast cancer with liver metastases
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of thermal therapy and immunotherapy for women with HER2-negative breast cancer that has spread to the liver. It aims to see if this treatment can help control the disease after previous treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer is HER2-negative and has spread to the liver.
- Your cancer has progressed after at least one prior treatment for advanced or metastatic disease.
- You must have at least one measurable tumor that hasn't been treated with radiation.
- You have no more than 10 liver tumors, each no larger than 4 cm, and no major liver blood vessel or bile duct involvement.
- Your liver and kidney function, and blood counts are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a combination of immune-targeting drugs (a CD40 medicine and a substance that helps immune cells act) plus chemotherapy in people with HER2-negative advanced breast cancer that has progressed. It aims to find a safer dose and see whether the treatment can shrink tumors or slow the cancer.
This trial tests a new treatment that uses heat to target liver tumors and boost the immune system. It is for women with breast cancer that has spread to the liver who cannot have or do not want surgery.
This study tests an experimental drug called SHR-1826, either alone or combined with an immunotherapy (a treatment that boosts your immune system to fight cancer), for people with advanced liver cancer who have already tried other treatments and they stopped working. The goal is to see if this new drug can help shrink tumors or slow the cancer's growth.
This trial tests a new drug, SHR-A1811, given alone or followed by a standard treatment, before surgery for early-stage HER2-positive breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.